MMED news

Medtronic plc completed the spin-off of MiniMed Group, Inc. and redeemed its remaining interest, marking a major strategic milestone.

MiniMed separated from its parent Medtronic after completing an exchange offer for its shares, marking the diabetes company's first day as a standalone entity focused on advancing its therapies.

MiniMed delivered strong Q1 2027 results with net sales of $843 million, aided by U.S. acceleration and robust international growth. The company raised fiscal year organic revenue guidance and highlighted key FDA submissions and product launches.

MIMEDX Group, Inc. has entered into an agreement and plan of merger with Sanara MedTech and Mustang Merger Sub to be acquired. The merger, valued at approximately $250 million ($500 million enterprise value), will result in the surviving corporation being a wholly owned subsidiary of Sanara MedTech.

MiniMed reported Q4 net sales of $837 million growing 16% reported and 9% organic, with full-year FY2026 sales reaching $3.102 billion, a company first. The company launched FDA-cleared MiniMed Flex and MiniMed Go systems while expanding international markets and CGM attachment rates to 68%.